Latest news
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea
Iconovo announces that the company will receive a grant of SEK 680,000 from Innowwide. The grant will be used to carry out a market study to introduce…
Biostock: Iconovo inleder 2024 med order från ledande läkemedelsbolag
Iconovo har erhållit en order från ett av världens tio största läkemedelsbolag. Dessutom stärker bolaget sin CDMO-affärsmodell genom att ingå ytterligare…
Press releases
Feb 15, 2024, 19:35
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Feb 15, 2024, 19:35
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 15, 2024, 19:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
mfn-cus-top-disclaimer
Feb 15, 2024, 19:30
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
mfn-cus-top-disclaimer
Feb 07, 2024, 14:50
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Feb 07, 2024, 14:50
News
IR
English
Regulatory
MAR
Corporate Action
Other
Feb 06, 2024, 14:45
News
IR
English
Corporate Action
Other
Feb 06, 2024, 14:45
News
IR
Swedish
Corporate Action
Other
Feb 01, 2024, 08:00
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
mfn-cus-disclaimer
Feb 01, 2024, 08:00
News
IR
English
Regulatory
MAR
Corporate Action
Other
mfn-cus-disclaimer
Jan 08, 2024, 09:00
News
IR
English
Corporate Action
Other
Jan 08, 2024, 09:00
News
IR
Swedish
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se